Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 2(110), p. 313-319, 2013

DOI: 10.1038/bjc.2013.722

Links

Tools

Export citation

Search in Google Scholar

Adjuvant chemotherapy in elderly patients with pancreatic cancer

Journal article published in 2014 by Chin Vt, A. M. Nagrial, Chang Dk, N. Q. Nguyen, Nguyen Nq, A. L. Johns, Chantrill La, J. L. Humphris, Humphris Jl, Samra Js, J. S. Samra, A. J. Gill, M. Pajic ORCID, M. Pinese, E. K. Colvin and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Background:Adjuvant chemotherapy improves survival for patients with resected pancreatic cancer. Elderly patients are under-represented in Phase III clinical trials, and as a consequence the efficacy of adjuvant therapy in older patients with pancreatic cancer is not clear. We aimed to assess the use and efficacy of adjuvant chemotherapy in older patients with pancreatic cancer.Methods:We assessed a community cohort of 439 patients with a diagnosis of pancreatic ductal adenocarcinoma who underwent operative resection in centres associated with the AUSn Pancreatic Cancer Genome Initiative.Results:The median age of the cohort was 67 years. Overall only 47% of all patients received adjuvant therapy. Patients who received adjuvant chemotherapy were predominantly younger, had later stage disease, more lymph node involvement and more evidence of perineural invasion than the group that did not receive adjuvant treatment. Overall, adjuvant chemotherapy was associated with prolonged survival (median 22.1 vs 15.8 months; P